Clinical Study

Pemphigus Vulgaris and Infections: A Retrospective Study on 155 Patients

Nafiseh Esmaili, 1,2 Hossein Mortazavi, 1,2,3 Pedram Noormohammadpour, 2 Majid Boreiri, 2 Tahereh Soori, 4 Iman Vasheghani Farahani, 5 and Mitra Mohit 6

1 Autoimmune Bullous Diseases Research Center, Tehran University of Medical Sciences, Tehran 1199663911, Iran
2 Department of Dermatology, Tehran University of Medical Sciences, Tehran 1199663911, Iran
3 Razi Hospital, Vahdat Islamic Square, Tehran 1199663911, Iran
4 Infectious Diseases Specialist, Razi Hospital, Tehran University of Medical Sciences, Tehran 1199663911, Iran
5 Sharif University of Technology, Tehran 136511555, Iran
6 Islamic Azad University, Tehran Medical Branch, Tehran 193951495, Iran

Correspondence should be addressed to Hossein Mortazavi; mortazma@sina.tums.ac.ir

Received 29 March 2013; Revised 19 May 2013; Accepted 2 June 2013

Academic Editor: Jozélio Freire de Carvalho

Copyright © 2013 Nafiseh Esmaili et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Background. Autoimmune process and immunosuppressive therapy of pemphigus vulgaris would predispose the patients to infections. Aim. We aimed to study the prevalence of infection and pathogenic agents in pemphigus vulgaris patients admitted to dermatology service. Material and methods. This retrospective study was conducted on 155 pemphigus vulgaris patients (68 males, 87 females) admitted to dermatology service between 2009 and 2011. In this study, the diagnosis of pemphigus vulgaris was confirmed by light microscopic and direct immunofluorescence findings. Data were collected through a questionnaire. Results. Of 155 pemphigus vulgaris patients, 33 had infection at admission and 9 acquired nosocomial infection. In addition, 37 cases of oral candidiasis and 15 cases of localized herpes simplex were recorded. Totally, 94 cases of infection were recorded. The occurrence of infection was significantly related to the severity of disease, number of hospital admissions, and presence of diabetes mellitus. The most common pathogenic germs isolated from cultures were Staphylococcus aureus and Escherichia coli. Conclusion. Severity of pemphigus vulgaris and diabetes were directly related with tendency to infections. Staphylococcus aureus and Escherichia coli were the most common pathogenic agents. Due to limitations of retrospective study, a prospective study is recommended.

1. Introduction

Pemphigus vulgaris (PV) and pemphigus foliaceus (PF) are organ-specific autoimmune bullous diseases characterized by loss of cell adhesion (acantholysis) and blister formation [1, 2]. These dermatoses are proven to be induced by autoimmune phenomenon [1–3]. Considering this etiology, immunosuppressive therapies are the main treatments available for these disorders. Infections are important complications in these patients attributable to disruption of the epidermal barrier due to the disease itself and immunosuppression induced by treatment [4, 5].

There are many reports regarding predisposition to infections due to immunosuppressive therapy and the immunocompromised state of pemphigus patients [6, 7].

PV has a high prevalence (30 per 100,000 inhabitants) in Iran; in this regard, we have studied this autoimmune disease from many different points of view [8–10]. The aim of the present study was to determine the rate of infection and pathogenic agents in PV patients admitted to dermatology inpatient service through a retrospective study.

2. Material and Methods

This retrospective study was performed on 155 PV patients (87 females, 68 males) admitted to the dermatology service of Razi Hospital of Tehran in Iran, between 2009 and 2011. The mean age of patients was 41.66 ± 13.29 years (range: 14–70). Of 155 admitted PV patients, 104 patients (67.10%) were first
In this study, 18 patients with mild disease treated with 2mg/kg/day prednisolone and 2.5mg/kg/day azathioprine had severe forms of the disease. According to the severity of disease, 43 patients (27.74%) had mild, 98 patients (63.23%) had moderate, and 14 patients (9.03%) had severe forms of the disease. Regardless of the severity of pemphigus, the patients were treated with 2mg/kg/day prednisolone and 2.5mg/kg/day azathioprine [12]. In this study, 18 patients with mild disease with upper limit of the normal range of liver function tests (aspartate aminotransferase = 42 U/L, alanine transaminase = 41 U/L) or lower limit of the normal range of white blood cells count (4 × 10^3/microliter or less) who were not suitable for azathioprine adjuvant therapy were treated with 2mg/kg/day prednisolone alone. 117 patients with mild, moderate, and severe disease (mild = 25, moderate = 88, and severe = 4) were treated with 2mg/kg/day prednisolone and 2.5mg/kg/day azathioprine. Twenty PV patients with moderate and severe disease (moderate = 10, severe = 10) with upper limit of the normal range of liver function tests who were not suitable for azathioprine adjuvant therapy were treated with 2mg/kg/day prednisolone and 2g/day (4 × 500 mg/day tablet) mycophenolate mofetil [13].

### Table 1: Prevalence of all infections in PV patients.

| Diagnosis                  | No. of patients (% of 155) | Treatment                             |
|----------------------------|-----------------------------|---------------------------------------|
| Oral candidiasis           | 37 (23.87%)                 | Systemic itraconazole Systemic Acyclovir |
| Herpes simplex             | 15 (9.68%)                  | According to pathogenic agent         |
| Skin infection             | 16 (10.32%)                 | According to pathogenic agent         |
| Urinary bacterial infection| 13 (8.39%)                  | Empirical regarding infectious man suggestion |
| Pulmonary infection        | 13 (8.39%)                  |                                       |
| All                        | 94 (60.65%)                 |                                       |

### Table 2: Frequency of infection regarding admission of patients (excluding oral candidiasis and herpes infections).

| Admission                  | Infection |
|----------------------------|-----------|
|                            | No. of patients (At admission) | Nosocomial infection | Sum |
| First admission            | 85 (15)  | 4 | 104  |
| Multiple admission         | 28 (18)  | 5 | 51   |

Admitted and the 51 remaining patients (32.90%) had multiple admissions. Patients with a clinical diagnosis of PV with compatible histopathology and direct immune fluorescence (DIF) findings confirming the clinical diagnosis of PV entered the study. Light microscopic and direct immunofluorescence findings in favor of pemphigus vulgaris were suprabasal bullae and acantholysis and IgG and C3 deposits in the intercellular regions of epidermis, respectively. The severity of PV was evaluated by a "severity index for pemphigus," namely, mild, moderate, and severe [11]. All of the PV patients contributing to this study (mild, moderate, and severe) were hospitalized in the dermatology wards of Zanjan Hospital regardless of severity of the disease. Accordingly, 43 patients (27.74%) had mild, 98 patients (63.23%) had moderate, and 14 patients (9.03%) had severe forms of the disease.

Regardless of the severity of pemphigus, the patients were treated with 2mg/kg/day prednisolone and 2.5mg/kg/day azathioprine [12]. In this study, 18 patients with mild disease with upper limit of the normal range of liver function tests (aspartate aminotransferase = 42 U/L, alanine transaminase = 41 U/L) or lower limit of the normal range of white blood cells count (4 × 10^3/microliter or less) who were not suitable for azathioprine adjuvant therapy were treated with 2mg/kg/day prednisolone alone. 117 patients with mild, moderate, and severe disease (mild = 25, moderate = 88, and severe = 4) were treated with 2mg/kg/day prednisolone and 2.5mg/kg/day azathioprine. Twenty PV patients with moderate and severe disease (moderate = 10, severe = 10) with upper limit of the normal range of liver function tests who were not suitable for azathioprine adjuvant therapy were treated with 2mg/kg/day prednisolone and 2g/day (4 × 500 mg/day tablet) mycophenolate mofetil [13].

### Table 3: Frequency of infection regarding severity of PV patients (excluding oral candidiasis and herpes infections).

| Severity   | No infection | At admission | Nosocomial infection | Total infection |
|------------|--------------|--------------|----------------------|----------------|
| Mild       | 36           | 7            | 0                    | 7              |
| Moderate   | 71           | 20           | 7                    | 27             |
| Severe     | 6            | 6            | 2                    | 8              |

The phenotype of PV recorded in order of frequency was mucocutaneous in 104 (67.10%), cutaneous in 30 (19.35%), and mucosal phenotype in 21 patients (13.55%).

Demographic data including age, gender, number of admissions, severity of the disease, underlying medical disorders such as history of diabetes and hypertension, treatment protocols, and infections recognized during the admission period were registered in the appropriate questionnaires. The ethical committee of Tehran University of Medical Sciences approved the study.

#### 2.1. Statistical Analysis

Data were collected by questionnaire and analyzed by statistical software, SPSS. Chi-square test and Student’s t-test were used for data analysis. P value less than 0.05 was assigned as statistically significant.

### 3. Results

In total 94 cases of infections were recorded (Table 1). Fifty two patients had a clinical diagnosis of oral candidiasis and localized oral herpes simplex. Excluding these 52 patients, 42 patients had pulmonary, bacterial skin, and urinary infections.

Excluding oral candidiasis and herpes infections, with regard to the rate of infection in men and women (20/68 versus 22/87), there was no statistically difference between the two genders.

From the 104 first admitted PV patients, 19 patients (18.27%) had infections; while from the 51 patients with multiple admissions to hospital, 23 (45.10%) had infections (P < 0.001) (Table 2).

With regard to 42 patients with pulmonary, bacterial skin, and urinary infections, 33 patients had infections at admission (day 0 to 2), while 9 patients were infected from day 3 and thereafter. Namely, these 9 patients had hospital-acquired infection (nosocomial infection).

Severity of the disease is shown in Table 3. Regarding the severity of disease, the rates of infection between mild, moderate, and severe were significantly different (P = 0.011).

With regard to 42 patients with pulmonary, bacterial skin, and urinary infections, 16 patients had skin infection, 13 patients had urinary infections, and 13 patients had pulmonary infections (Table 1). The results of cultures of skin and urinary tract infections and percentage of resistant antibiotic to pathogenic agents are shown in Table 4.

Table 5 presents the data regarding the relationship between type of drug therapy regimen with frequency of...
Table 4: Pathogenic agents and percentage of resistance to antibiotics in order of frequency in skin and urinary tract infections of PV patients.

| Site of involvement | Germ               | Percentage | Resistant to antibiotic | Percentage |
|---------------------|--------------------|------------|-------------------------|------------|
| Skin                | Staphylococcus aureus | 15 (93.7%) | Penicillin              | 60%        |
|                     |                    |            | Cefazolin               | 40%        |
|                     |                    |            | Cephalexin              | 26.7%      |
|                     |                    |            | Ampicillin              | 20%        |
|                     |                    |            | Clindamycin             | 20%        |
|                     |                    |            | Vancomycin              | 13.3%      |
|                     |                    |            | Cefizoxime              | 13.3%      |
|                     |                    |            | Cefotaxime              | 6.7%       |
|                     | Other              | 1 (6.3%)   | Cefixime                | 57.1%      |
|                     |                    |            | Gentamicin              | 57.1%      |
|                     |                    |            | TMP                     | 42.8%      |
| Urinary tract       | Escherichia coli   | 7 (53.8%)  | Ampicillin              | 28.6%      |
|                     |                    |            | Amikacin                | 28.6%      |
|                     |                    |            | Ciprofloxacin           | 28.6%      |
|                     |                    |            | Cefotaxime              | 14.3%      |
|                     | Pseudomonas        | 2 (15.4%)  | Gentamicin              | 100%       |
|                     |                    |            | Cefixime                | 50%        |
|                     |                    |            | Amikacin                | 50%        |
|                     | Proteus            | 1 (7.8%)   | Ampicillin              | 100%       |
|                     |                    |            | Cefixime                | 100%       |
|                     | Other              | 3 (23.0%)  | TMP                     | 66.7%      |
|                     |                    |            | Ampicillin              | 33.3%      |

Table 5: Frequency of infections regarding regimen of immunosuppressive therapy (excluding oral candidiasis and herpes infections).

| Type of drug therapy | No infection | Infection At admission | Nosocomial infection | Total infection |
|----------------------|--------------|------------------------|----------------------|-----------------|
| Prednisolone         | 14           | 4                      | 0                    | 4               |
| Prednisolone + azathioprine | 88       | 20                     | 9                    | 29              |
| Prednisolone + mycophenolate mofetil | 11   | 9                      | 0                    | 9               |

Infections. The difference between 3 immunosuppressive therapy regimens was not significant ($P = 0.151$).

Of 155 patients, 14 patients were diabetic. The rate of infection in diabetic versus nondiabetic PV patients was 50% and 24.82%, respectively ($P = 0.044$).

In PV patients with nosocomial infection, the mean duration between admission to hospital and onset of infection was 13.22 ± 5.7 day (range: 4–22). The mean dose of prednisolone at the time of nosocomial infection onset was 55.8 ± 17.9 mg/day.

No mortality was recorded in this study.

4. Discussion

PV is a well-known autoimmune disease [14]. Nowadays, the relationship between autoimmunity, immunodeficiency, and infection is well recognized. It is believed that autoimmunity and immunodeficiency are not separate entities, but rather some connection exists between them [15, 16]. On the other hand, hospitalization in addition to immunosuppressive therapy would predispose the PV patients to infection.

Our search in the literature revealed some similar studies performed in other countries [6]. In our study, 60.6% of PV patients had infections, while in the study of Belgnaoui et al., 68% of patients had infections. Overall, our results are similar to the study of Belgnaoui et al. The small differences between the two studies may be due to differences in severity of disease and duration of hospitalization [6].

The study of Ljubojević et al. on 159 PV patients during 19 years revealed several complications associated with high doses of corticosteroids and immunosuppressive therapy [17]. These complications were as follows: skin infection in 26 patients (16.35%), sepsis in 9 patients (5.66%), and 14 patients (8.81%) died during the period of hospitalization. With regard to skin infection, the results of the Ljubojević et al. study are similar to those of the present study. The absence of sepsis and death in our study may be due to the small number of patients with severe PV and the shorter period of our study.
In our study, the occurrence of infection had a direct relationship with disease severity, and the difference between mild and severe was significant. In Ljubojević et al’s study, severe cutaneous and mucosal involvement was also consistent with a higher mortality rate [17].

Mourellou et al. followed 48 patients for 11 years; they concluded that complications and mortality rate of PV were related to the severity of PV. Our study is consistent with the study by Mourellou et al. [18].

In the current study, the rate of infection in PV patients with diabetes was significantly higher than in nondiabetics ($P = 0.044$). Belgnaoui et al. also reported more severe bacterial infection in diabetics PV patients [6].

In our study, the rate of infection in patients receiving immunosuppressive adjuvants plus systemic steroids was not significantly different from patients receiving corticosteroids alone. This means that all PV patients receiving corticosteroids (with or without advent immunosuppressive) are prone to infections. It should be noted that we did not include the PV patients treated with rituximab (which may be a susceptibility factor for infection). Kim et al. found that there was no difference in prednisolone alone or prednisolone plus adjuvant with regard to prognosis and time to remission in PV patients [19].

Most bacterial skin infections detected in our patients were due to *Staphylococcus aureus*. In other studies in PV patients, skin infections due to *Staphylococcus aureus* have been reported as well [20]. In the study by Kanwar and Dhar, among the causes of 10 deaths of PV, sepsis was the most common cause of urinary tract infections in the general population [22].

Escherichia coli was the most frequent cause of urinary tract infection in our study. Obviously, *Escherichia coli* is the most common cause of urinary tract infections in the general population [22].

In the current study, 9.68% of patients had localized herpes simplex infection, while in the study of Belgnaoui et al. 17% of patients had localized herpes infection [6]. In several reports, the herpes infection has been studied in PV patients [6, 23, 24]. Although high doses of corticosteroid and immunosuppressive therapy would cause patients to be prone to an extensive herpes simplex virus infection, in this study, we had only localized herpes simplex virus infections [24]. Previously, our group had studied the herpes simplex infection and PV in German patients [10]. In that study we concluded that a herpes virus infection occasionally is responsible for exacerbation of PV [10].

In the current study, 23.87% of patients had oral candidiasis, while in the study of Belgnaoui et al. 30% of patients had oral candidiasis [6]. With regard to oral candidiasis, the result of the two studies is similar. Previously, laryngeal candidiasis has been reported in patients with PV, but in this study we had only localized oral candidiasis [25].

Infection rate had a positive significant relationship with the number of admission sessions. Patients with multiple admission sessions had a rate of infection approximately two times more than patients admitted for first time. Logically, patients with a more severe disease would have more admissions, and consequently the rate of infections would increase.

Retrospective nature and relatively short period of the study (2 years) are major limitations of this project. Another limitation of the study is PV patients on different immunosuppressive adjuvant therapy included in this study. A prospective study with followup is recommended.

We concluded that PV patients with multiple admission sessions, diabetes mellitus, and severe disease are at higher risk of infection. According to a high rate of antimicrobial resistance, antibiograms are recommended for antibiotic therapy.

References

[1] D. S. Buzina and B. Marinović, “From pemphix to desmogleins,” *Clinics in Dermatology*, vol. 29, no. 4, pp. 355–359, 2011.

[2] P. R. Cunha and S. R. C. S. Barraviera, “Autoimmune bullous dermatoses,” *Anais Brasileiros de Dermatologia*, vol. 84, no. 2, pp. III–122, 2009.

[3] S. A. Grando, “Pemphigus autoimmunity: hypotheses and realities,” *Autoimmunity*, vol. 45, no. 1, pp. 7–35, 2012.

[4] A. Razzaque Ahmed and R. Moy, “Death in pemphigus,” *Journal of the American Academy of Dermatology*, vol. 7, no. 2, pp. 221–228, 1982.

[5] T. Piamphongsant and S. Ophaswongse, “Treatment of pemphigus,” *International Journal of Dermatology*, vol. 30, no. 2, pp. 139–146, 1991.

[6] F. Z. Belgnaoui, K. Senouci, H. Chraibie et al., “Predisposition to infection in patients with pemphigus. Retrospective study of 141 cases,” *Presse Medicale*, vol. 36, no. 11, part 1, pp. 1563–1569, 2007.

[7] M.-J. Ko and C.-Y. Chiu, “Disseminated human papillomavirus type 11 infection in a patient with pemphigus vulgaris: confirmed by DNA analysis,” *Journal of the American Academy of Dermatology*, vol. 51, no. 5, pp. S190–193, 2004.

[8] C. Chams-Davatchi, M. Valikhani, M. Daneshpazhooh et al., “Pemphigus: analysis of 1209 cases,” *International Journal of Dermatology*, vol. 44, no. 6, pp. 470–476, 2005.

[9] C. Chams-Davatchi, “Prevalence and treatment of pemphigus in Iran,” *Dermatologic Clinics*, vol. 29, no. 4, pp. 681–683, 2011.

[10] N. Esmaili, Z. Hallaji, R. Abedini, T. Soori, H. Mortazavi, and H. Gorji, “Skin infection in patients with pemphigus. Retrospective study of 141 cases,” *Presse Medicale*, vol. 36, no. 11, part 1, pp. 1563–1569, 2007.

[11] S. Ikeda, S. Imamura, I. Hashimoto, S. Morioka, M. Sakuma, and H. Ogawa, “History of the establishment and revision of diagnostic criteria, severity index and therapeutic guidelines for pemphigus in Japan,” *Archives of Dermatological Research*, vol. 295, supplement 1, pp. S12–S16, 2003.

[12] C. Chams-Davatchi and M. Daneshpazhooh, “Prednisolone dosage in pemphigus vulgaris,” *Journal of the American Academy of Dermatology*, vol. 53, no. 3, p. 547, 2005.

[13] S. Beissert, T. Werfel, U. Fritling et al., “A comparison of oral methylprednisolone plus azathioprine or mycophenolate mofetil for the treatment of bullous pemphigoid,” *Archives of Dermatology*, vol. 143, no. 12, pp. 1536–1542, 2007.

[14] M. Hertl and R. Eming, “Autoimmune skin disorders, pemphigus,” in *Autoimmune Diseases of the Skin (Pathogenesis, Diagnosis, Management)*, M. Hertl, Ed., pp. 33–63, Springer, Wien, Austria, 2011.

[15] A. P. Grammatikos and G. C. Tsokos, “Immunodeficiency and autoimmunity: lessons from systemic lupus erythematosus,” *Trends in Molecular Medicine*, vol. 18, no. 2, pp. 101–108, 2012.
[16] T. P. Atkinson, "Immune deficiency and autoimmunity," Current Opinion in Rheumatology, vol. 24, no. 5, pp. 515–521, 2012.
[17] S. Ljubojević, J. Lipozenčić, S. Brenner, and D. Budimčić, "Pemphigus vulgaris: a review of treatment of over a 19-year period," Journal of the European Academy of Dermatology and Venereology, vol. 16, no. 6, pp. 599–603, 2002.
[18] O. Mourellou, G. C. Chaidemenos, T. Koussidou, and E. Kapetis, "The treatment of pemphigus vulgaris. Experience with 48 patients seen over an 11-year period," British Journal of Dermatology, vol. 133, no. 1, pp. 83–87, 1995.
[19] M. R. Kim, H. C. Kim, and S.-C. Kim, "Long-term prognosis of pemphigus in korea: retrospective analysis of 199 patients," Dermatology, vol. 223, no. 2, pp. 182–188, 2011.
[20] N. Chmurova and D. Svecova, "Pemphigus vulgaris: a 11-year review," Bratislavské Lekárske Listy, vol. 110, no. 8, pp. 500–503, 2009.
[21] A. J. Kanwar and S. Dhar, "Factors responsible for death in patients with pemphigus," Journal of Dermatology, vol. 21, no. 9, pp. 655–659, 1994.
[22] A. R. Brumbaugh and H. L. Mobley, "Preventing urinary tract infection: progress toward an effective Escherichia coli vaccine," Expert Review of Vaccines, vol. 11, no. 6, pp. 663–676, 2012.
[23] K. Zouhair, T. El Ouazzani, S. Azzouzi, S. Sqalli, and H. Lakhdar, "Herpes simplex infections in pemphigus: 6 cases," Annales de Dermatologie et de Venereologie, vol. 126, no. 10, pp. 699–702, 1999.
[24] A. L. Y. Lecluse and C. A. F. M. Bruijnzeel-Koomen, "Herpes simplex virus infection mimicking bullous disease in an immunocompromised patient," Case Reports in Dermatology, vol. 2, no. 2, pp. 99–102, 2010.
[25] E. K. Hale and J.-C. Bystryn, "Laryngeal and nasal involvement in pemphigus vulgaris," Journal of the American Academy of Dermatology, vol. 44, no. 4, pp. 609–611, 2001.